DNA, DNABW · CIK 0001830214 · operating
Ginkgo Bioworks operates a cell programming platform designed to enable the development and commercialization of engineered organisms and derived products. The company provides cell engineering research and development solutions alongside proprietary tools, including functional genomics services, antibody developability assessment, artificial intelligence models, and reconfigurable automation systems. These offerings support clients in the pharmaceutical, biotechnology, agriculture, industrial, environment, food and nutrition, consumer, technology, and government sectors.
The company operates through two primary segments: Cell Engineering and Biosecurity. The Cell Engineering segment delivers the core platform services and tools for organism engineering and product development. The Biosecurity segment includes Canopy, a biomonitoring program that generates genomic data through strategically positioned monitoring nodes, and Horizon, a digital surveillance and analytics platform designed to detect and monitor biological threats.
Ginkgo Bioworks was founded in 2008 and is headquartered in Boston, Massachusetts, with approximately 834 full-time employees. The company is incorporated in Delaware and trades on the New York Stock Exchange under the ticker DNA.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-5.64 | $-5.64 | +46.5% | |
| 2024 | $-10.54 | $-10.54 | -2191.3% | |
| 2023 | $-0.46 | $-0.46 | +63.2% | |
| 2022 | $-1.25 | $-1.25 | +10.1% | |
| 2021 | $-1.39 | $-1.35 | — |